634 EVEREST-1: A seamless phase 1/2 study of CEA logic-gated Tmod CAR T-cell therapy (A2B530) in patients with solid tumors associated with CEA expression also exhibiting HLA loss of heterozygosity (LOH)

Salman R Punekar ,Marwan Fakih,Maria Pia Morelli ,Caleb J Smith ,Theodore H Welling ,John S Welch ,Eric Ng ,Julian R Molina ,Tomislav Dragovich ,Jennifer M Specht ,Kedar Kirtane ,Patrick Grierson ,Sarah Nikiforow ,Kirstin B Liechty ,Scott Kopetz ,William Y Go ,David G Maloney ,Sandip Pravin Patel ,Matthew J Frigault ,Armen Mardiros ,Frederick L Locke ,Jeffrey D Ward ,Edward B Garon ,Ariane Lozac’hmeur ,Yi Lin ,Judy Vong ,Wen‐Kai Weng ,J Randolph Hecht ,Marcela V Maus ,Diane M Simeone

doi:10.1136/jitc-2023-sitc2023.0634

634 EVEREST-1: A seamless phase 1/2 study of CEA logic-gated Tmod CAR T-cell therapy (A2B530) in patients with solid tumors associated with CEA expression also exhibiting HLA loss of heterozygosity (LOH)

Salman R Punekar , Marwan Fakih + Show 28 more

Open Access

PDF Available

https://doi.org/10.1136/jitc-2023-sitc2023.0634

Copy DOI

Export

Save

Cite

Journal: Journal for ImmunoTherapy of Cancer	Publication Date: Nov 1, 2023
License type: CC BY-NC 4.0

Affiliation: City Of Hope National Medical Center

#Carcinoembryonic Antigen #Loss Of Heterozygosity #Carcinoembryonic Antigen Expression #Off-tumor Toxicities #Human Leukocyte Antigen #Recommended Phase 2 Dose #Primary Objective Of Phase #Therapies In Solid Tumors #Line Of Prior Therapy #Solid Tumors

Abstract
Full-Text PDF
Similar Papers

Abstract

Listen

BackgroundChimeric antigen receptor (CAR) T-cell therapy has demonstrated clinical efficacy in hematologic malignancies1; however, implementation of these therapies in solid tumors has been challenging due to a lack of tumor-specific...

Full Text

Published Version (Free)

View/Download pdf

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Journal for ImmunoTherapy of Cancer

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.

R Discovery Prime

634 EVEREST-1: A seamless phase 1/2 study of CEA logic-gated Tmod CAR T-cell therapy (A2B530) in patients with solid tumors associated with CEA expression also exhibiting HLA loss of heterozygosity (LOH)